Effects of postoperative radiotherapy on cardiovascular-pulmonary disease mortality in patients with stage IIIA-N2 resected NSCLC: analysis of the SEER database.

Xia Wang, Jiaqi Song, Jie Long, Zhimin Zeng, Anwen Liu

Abstract read

In one paragraph

Article in Radiation oncology (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed, 1 pooled it

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

Network meta-analysis on the efficacy and safety of management for resectable stage IIIA-N2 non-small cell lung cancer.BMC cancer · 2024
Pooled it
Radiotherapy Reprograms Intermediate Monocytes Into Proinflammatory Drivers of Systemic Inflammation in Radiation-Induced Heart Disease.Cardiology research and practice · 2026
Article
The high-risk features and effect of postoperative radiotherapy on survival for patients with surgically treated stage IIIA-N2 non-small cell lung cancer.World journal of surgical oncology · 2023
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xia WangDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Street, Nanchang, 330000, Jiangxi Province, People's Republic of China.ORCID http://orcid.org/0000-0002-6986-0979

Jiaqi SongDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Street, Nanchang, 330000, Jiangxi Province, People's Republic of China.

Jie LongDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Street, Nanchang, 330000, Jiangxi Province, People's Republic of China.

Zhimin ZengDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Street, Nanchang, 330000, Jiangxi Province, People's Republic of China.

Anwen LiuDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Street, Nanchang, 330000, Jiangxi Province, People's Republic of China. awliu666@163.com.

Funding

National Natural Science Foundation of China 81760566National Natural Science Foundation of China 82060577

6 · The paper itself

Abstract

backgroundThe role of postoperative radiotherapy (PORT) in cardiovascular-pulmonary disease mortality in patients with stage IIIA-N2 resected non-small cell lung cancer (NSCLC) remains uncertain. The purpose of this population-based analysis was to explore the effect of PORT on cardiovascular-pulmonary disease mortality in these patients.

methodsPatients aged ≥ 18 years with stage IIIA-N2 resected NSCLC were identified in the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2015 and were grouped according to the use of PORT. Propensity score matching (PSM) was used to account for differences in baseline characteristics between the Non-PORT and PORT groups. The cumulative risk for cardiovascular-pulmonary disease death was estimated using the cumulative incidence curve. Competing risk regression was used to run univariate and multivariate analyses to evaluate risk factors.

resultsA total of 3981 patients were included in the study population. Among them, 1446 patients received PORT, and 2535 did not. A total of 1380 patients remained in each group after PSM, and the baseline characteristics were not significantly different between the two groups. The cumulative incidence of cardiovascular-pulmonary mortality was 10.93% in the Non-PORT group compared with 9.85% in the PORT group. There was no significant difference in the cumulative risk between the two groups (HR 1.07, 95% CI 0.77-1.48, p = 0.703). Multivariate analysis indicated that PORT had no significant impact on increased risk, with an HR of 1.18 (p = 0.377).

conclusionsNo significant differences between the PORT and Non-PORT groups were found in cardiovascular-pulmonary-specific modalities in this study. Further studies are required to validate these results. This study highlights the importance of long-term surveillance for NSCLC patients.

Indexed as

AdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungCardiovascular DiseasesCombined Modality TherapyHumansLung DiseasesLung NeoplasmsMiddle AgedNeoplasm StagingRisk FactorsSEER ProgramYoung AdultCardiovascular-pulmonary disease mortalityNon-small cell lung cancerPostoperative radiotherapyPropensity score matchingSEERStage IIIA-N2

Identifiers

PMID34544464

DOI10.1186/s13014-021-01912-4

PMCPMC8453996

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.